Chartoreg Co 10/40mg, 5/80mg & 10/80mg

INDICATIONS AND USAGE

Chartoreg Co (amlodipine/ telmisartan) tablets are indicated for the treatment of hypertension, alone

or with other antihypertensive agents to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes

and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive

drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and

dihydropyridine calcium channel blockers.

Control of high blood pressure should be part of comprehensive cardiovascular risk management,

including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking

cessation, exercise, and limited sodium intake. Many patients will require more than one drug to

achieve blood pressure goals.

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different

mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular

morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some

other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest

and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but

reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk

increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe

hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is

similar across populations with varying absolute risk, so the absolute benefit is greater in patients

who are at higher risk independent of their hypertension (for example, patients with diabetes or

hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a

lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients,

and many antihypertensive drugs have additional approved indications and effects (e.g., on angina,

heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Chartoreg Co tablets may also be used as initial therapy in patients who are likely to need multiple

drugs to achieve their blood pressure goals.

Base the choice of Chartoreg Co tablets as initial therapy for hypertension on an assessment of

potential benefits and risks including whether the patient is likely to tolerate the starting dose of

Chartoreg Co tablets.

Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events

(such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt

treatment is clinically relevant. Consider the patient's baseline blood pressure, the target goal, and

the incremental likelihood of achieving goal with a combination compared with monotherapy when

deciding whether to use Chartoreg Co tablets as initial therapy. Individual blood pressure goals may

vary based upon the patient’s risk.